Iatrogenic QT abnormalities and fatal arrhythmias: Mechanisms and clinical significance

Current Cardiology Reviews

Volumn 5, Issue 3, 2009, Pages 166-176

  Cubeddu, Luigi X ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Drug induced; HERG potassium channels; Long QT; Torsades de pointe

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; AZITHROMYCIN; CALCIUM CHANNEL L TYPE; CIPROFLOXACIN; CLARITHROMYCIN; DOFETILIDE; ERYTHROMYCIN; FLUOXETINE; GATIFLOXACIN; GLYCOSIDE; GREPAFLOXACIN; KETOCONAZOLE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NEUROLEPTIC AGENT; NORFLUOXETINE; OFLOXACIN; PENTAMIDINE; POTASSIUM CHANNEL HERG; QUINIDINE DERIVATIVE; SOTALOL; SPARFLOXACIN; UNINDEXED DRUG;

ANAMNESIS; BRADYCARDIA; CARDIOVERSION; CLINICAL TRIAL; DEFIBRILLATOR; DRUG ACTIVITY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG POTENCY; ENDOPLASMIC RETICULUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HEART ARREST; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; IATROGENIC DISEASE; LOSS OF FUNCTION MUTATION; PATHOGENESIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QT INTERVAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SHORT QT SYNDROME; SYMPTOMATOLOGY; SYSTOLIC DYSFUNCTION; T WAVE; TACHYCARDIA; TORSADE DES POINTES;

EID: 70449623537     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340309788970397     Document Type: Review

References (107)

1. Roden DM. Long QT syndrome and torsades de pointes: basic and clinical aspects. In: Cardiac Pacing and Electrophysiology. El-Sherif, N, Samet P, Eds. WB Saunders Co, Philadelphia 1991; 265-284
2. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. BMJ 2000; 320: 1158-1159 (Pubitemid 30224261)
3. Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003; 10: 452-457
4. Morissette P, Hreiche R, Turgeon J. Drug-induced long QT syndrome and torsade de pointes Can J Cardiol 2005; 21: 857-864
5. Kannankeril J, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 2007; 22: 39-43.
6. Woosley RL. Drugs That Prolong the Q-T Interval and/or Induce Torsades de Pointes. Updated October 23, 2001. Available at http://www.torsades.org and at http://www.Qtdrugs.org Accessed January 29, 2008.
7. SoRelle R. Warnings strengthened on tranquilizer inapsine [Droperidol]. Circulation 2001;104: E 9061-9062
8. Slama R, Motte G, Coumel P, Dessertenne F. The syndrome, "QT lengthening and syncope due to torsion of the points". Laval Med 1971; 42: 353-366
9. Dessertenne F, Coumel P, Fabiato A. Ventricular fibrillation and torsades de pointes. Cardiovasc Drugs Ther 1990; 4: 1177-1182
10. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J 2001; 3: K70-K80. (Pubitemid 32910785)
11. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 2007; 4: 608-610
12. Moss AJ. The QT interval and Torsades de Pointes. Drug Saf 1999; 21: 5-10.
13. Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 2006; 3: 1003-1007 (Pubitemid 44283697)
14. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factors for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590-2597
15. Newton-Cheh C, Guo CY, Wang TJ, O'donnell CJ, Levy D, Larson MG. Genome-wide association study of electrocardiographic and heart rate variability traits: the Framingham Heart Study. BMC Med Genet 2007; 8: S7.
16. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115-172 (Pubitemid 18234881)
17. Choi BR, Burton F, Salama G. Cytosolic Ca2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome. J Physiol 2002; 543: 615-631 (Pubitemid 35012214)
18. Jiashin Wu, PhD; Jianyi Wu, MD, Douglas P. Zipes, MD. Early Afterdepolarizations, U Waves, and Torsades de Pointes. Circulation 2002; 105: 770-774
19. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-803.
20. Sanguinetti MS, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ikr potassium channel. Cell 1995; 81: 299-307.
21. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical electrophysiology, clinical QT interval prolongation and Torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32-45. (Pubitemid 36351620)
22. Van de Loo A, Klingenheben T, Hohnloser SH. Amiodarone therapy after previous sotalol-induced torsade de pointes: analysis of AT dispersion to predict proarrhythmia. J Cardiovasc Pharmacol Ther 1996; 1: 75-78
23. Tran HT, Chow MS, Kluger J. Amiodarone induced torsades de pointes with excessive QT dispersion following quinidine induced polymorphic ventricular tachycardia. Pacing Clin Electrophysiol 1997; 9: 2275-2278
24. Veglio M, Giunti S, Stevens LK, Fuller JH, Perin PC, EURODIAB IDDM Complications Study Group. Prevalence of Q-T interval dispersion in type 1 diabetes and its relation with cardiac ischemia: the EURODIAB IDDM Complications Study Group. Diabetes Care 2002; 25: 702-707
25. Antzelevitch C. Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes Europace 2007; 9: 4-15.
26. Little RE, Kay GN, Cavender JB, Epstein AE, Plum VJ. Torsades de pointes and T-U wave alternans associated with arsenic poisoning. Pacing Clin Electrophysiol 1990; 13: 164-167
27. Narayan SM. T-wave alternans and the susceptibility to ventricular arrhythmias. J Am Coll Cardiol 2006; 47: 269-281
28. Vrtovec B, Delgado R, Zewail A, Thomas CD, Richartz BM, Radovancevic B. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation 2003; 107: 1764-1769 (Pubitemid 36418357)
29. Vrtovec B, Radovancevic R, Thomas CD, Yazdabakhsh AP, Smart FW, Radovancevic B. Prognostic value of the QTc interval after cardiac transplantation. J Heart Lung Transplant 2006; 25: 29-35. (Pubitemid 43049661)
30. Rana BS, Lim PO, Naas AA, Ogston SA, Newton RW, Jung RT, Morris AD, Struthers AD. QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. Heart 2005; 91: 44-50.
31. Psallas M, Tentolouris N, Papadogiannis D, et al. QT dispersion: comparison between participants with Type 1 and 2 diabetes and association with microalbuminuria in diabetes. J. Diabetes Complications 2006; 20: 88-97. (Pubitemid 43295374)
32. Sani MU, Okeahialam BN. QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc 2005; 97: 1657-1661
33. Roden DM, Spooner PM. Inherited long QT syndromes: a paradigm for understanding arrhythmogenesis. J Cardiovasc Electrophysiol 1999; 10: 1664-1683
34. Witchel HJ, Hancox JC. Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol 2000; 27: 753-766
35. Kahn IA. Long QT syndrome: diagnosis and management. Am Heart J 2002; 143: 7-14.
36. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006; 440: 463-469
37. Vincent GM. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med 1998; 49: 263-274
38. Wang Q, Bowles NE, Towbin JA. The molecular basis of long QT syndrome and prospects for therapy. Mol Med Today 1998; 4: 382-388 (Pubitemid 28411032)
39. Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97: 175-187 (Pubitemid 129746810)
40. Eckhardt LL, Rajamani S, January CT. Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome. Br J Pharmacol 2005; 145: 3-4. (Pubitemid 40675542)
41. Zhou Z, Gong O, Epstein ML, January CT. HERG Channel Dysfunction in Human Long QT Syndrome: intracellular transport and functional defects. J Biol Chem 1998; 273: 21061-21066 (Pubitemid 28385391)
42. Anna K, Zhihui Yu, Glenn IF, Thomas V. McDonald. The Dominant Negative LQT2 Mutation A561V Reduces Wild-type HERG Expression. J Biol Chem 2000; 275: 11241-11248
43. Zhou Z, Gong Q, January CT. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome: pharmacological and temperature effects. J Biol Chem 1999; 274: 31123-31126 (Pubitemid 129501552)
44. Ficker E, Obejero-Paz CA, Zhao S, Brown A. The binding site for channel blockers that rescue misprocessed human long QT síndrome type 2-ether-a-go-go-related gene [HERG]mutations. J Biol Chem 2002; 277: 4989-4998
45. Ficker E, Dennis AT, Wang L, Brown AM. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 2003; 92: 87-100.
46. Yang T, Roden DM. Extracellualr potassium modulation of drug blockade of IKr: implications for torsades de pointes and reverse use dependence. Circulation 1996; 93: 407-411 (Pubitemid 126425247)
47. Vorperian VR, Zhou Z, Mohammed S. Torsades de Pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996; 28: 1556-1561 (Pubitemid 26391863)
48. Choi AM, Lang CC, Chomsky DM, Rayos GH, Wilson JR, Roden DM. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997; 96: 2149-2154
49. Etheridge SP, Compton ST, Tristani-Firouzi M, Mason JW. A new oral therapy for long QT syndrome: log-term oral potassium supplementation improves repolarization in patients with HERG mutations. J Am Coll Cardiol 2003; 42: 1777-1782 (Pubitemid 37433657)
50. Dilaveris PE. Molecular predictors of drug-induced prolongation of the QT interval. Curr Med Chem Cardiovasc Hematol Agents 2005; 3: 105-118
51. Yang T, Snyders D, Roden DM. Drug block of I[Kr]: model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001; 38: 737-744 (Pubitemid 32983280)
52. Kääb S, Hinterseer M, Näbauer M, Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilot study using i.v. sotalol. Eur Heart J 2003; 24: 649-657 (Pubitemid 36343198)
53. Farkas A, Lepran I, Papp JG. Proarrhythmic Effects of Intravenous Quinidine, Amiodarone, d-Sotalol, and Almokalant in the Anesthetized Rabbit Model of Torsade de Pointes. J Cardiovasc Pharmacol 2002; 39: 287-297
54. Milberg P, Reinsch N, Osada N, et al. Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol 2005; 100: 365-371 (Pubitemid 40974087)
55. Waldo AL, Camm AJ, de Ruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348: 7-12.
56. Rizza C, Valderrabano M, Singh BN. Recurrent torsades de pointes after sotalol therapy for symptomatic paroxysmal atrial fibrillation in a patient with end-stage renal disease. J Cardiovasc Pharmacol Ther 1999; 4: 129-134 (Pubitemid 29256917)
57. Thomsen MB, Verduyn SC, Stengl M, et al. Increased short-term variability of repolarization predicts D-sotalol-induced torsade de pointes in dogs. Circulation 2004; 110: 2456-2459
58. Nkomo VT, Shen WK. Amiodarone-induced long QT and polymorphic ventricular tachycardia. Am J Emerg Med 2001; 19: 246-248 (Pubitemid 32378676)
59. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001; 104: 2722-2727 (Pubitemid 33108141)
60. Wang L, Wible BA, Wan X, Ficker E. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther 2007; 320: 525-534 (Pubitemid 46147930)
61. Smith AH, Norris KJ, Roden DM, Kannankeril PJ. Autonomic tone attenuates drug-induced QT prolongation. J Cardiovasc Electrophysiol 2007; 18: 960-964
62. Wolpert C, Schimpf R, Veltmann C, Borggrefe M. Short QT syndrome. Herz 2007; 32: 206-210
63. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 2004; 43: 1494-1499
64. De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HG, Hoes AW. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol 2007; 63: 216-223
65. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine 2003; 82: 282-290 Review. (Pubitemid 36859224)
66. Owens RC. Risk assessment of antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001; 21: 301-319
67. Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 2002; 303: 218-225 (Pubitemid 35056471)
68. Frothinghan R. Rates of torsades de pointes associated with ciprofluoxazine, ofloxazin, levofloxazine, gatifluoxazine and moxifluoxazine. Pharmacotherapy 2001; 21: 1468-1472
69. Anderson ME, Mazur A, Yang T, Roden DM. Potassium current antagonistics properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001; 296: 806-810 (Pubitemid 32187351)
70. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59: 122-126 (Pubitemid 32043093)
71. Lu HR, Vlaminckx E, Van de Water A, Gallacher DJ. Calmodulin antagonist W-7 prevents sparfloxacin-induced early after-depolarizations [EADs] in isolated rabbit prukinge fibers: importance of beat-to-beat instability of the repolarization. J Cardiovasc Electrophysiol 2006; 17: 415-422
72. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 41: 1859-1866
73. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007; 29: 374-379
74. Bibler MR, Chou TC, Toltzis RJ, Wade PA. Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity. Chest 1988; 94: 1303-1306 (Pubitemid 19002808)
75. Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne PE Jr, Wortham DC. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 1994; 105: 389-394
76. Kuryshev YA, Ficker E, Wang L, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 2005; 312: 316-323 (Pubitemid 40096484)
77. Letsas KP, Alexanian IP, Pappas LK, et al. QT interval prolongation and torsade de pointes associated with indapamide. Int J Cardiol 2006; 112: 373-374 (Pubitemid 44415035)
78. Delpon E, Valenzuela C, Tamargo J. Block of cardiac potassium and other channels by antihistaminics. Drug Saf 1991; 21: 11-18
79. Siddiqui MA, Keam SJ. Spotlight on ranolazine in chronic stable angina pectoris. Am J Cardiovasc Drugs 2006; 6: 357-359 (Pubitemid 44749346)
80. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005; 26: 720-723
81. No authors. Domperidone and sudden death. Prescrire Int 2006; 15: 226.
82. Medicines Control Council. Interaction between ketoconazole and domperidone and the risk of QT prolongation - important safety information. S Afr Med J 2006; 96: 596.
83. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048-1052 (Pubitemid 30162807)
84. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsades de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-1782
85. Kim KS, Kim EJ. The phenothiazine drugs inhibit hERG potassium channels. Drug Chem Toxicol 2005; 28: 303-313
86. Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238-240 (Pubitemid 28057213)
87. Silvestre JS, Prous JR. Comparative evaluation of hERG potassium channel blockade by antipsychotics Methods Find Exp Clin Pharmacol 2007; 29: 457-465
88. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev 2005; 24: 205-214 (Pubitemid 43060627)
89. Rajamani S, Eckhardt LL, Valdivia CR, et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 2006; 149:481-489 (Pubitemid 44658508)
90. Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000; 133: 881-885
91. Ficker E, Kuryshev YA, Dennis AT, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004; 66: 33-44 (Pubitemid 38822085)
92. Milberg P, Fleischer D, Stypmann J, et al. Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by IKr blockers. Basic Res Cardiol 2007; 102: 42-51. (Pubitemid 44932770)
93. Justo D, Zeltser D. Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports. Mycoses 2006; 49: 463-470 (Pubitemid 44511096)
94. Takemasa H, Nagatomo T, Abe H, et al. Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br J Pharmacol 2008; 153(3): 439-537
95. Drici MD, Clement N: Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001; 24: 575-585
96. Arya A. Gender-related differences in ventricular repolarization: beyond gonadal steroids. J Cardiovasc Elctrophysiol 2005; 16: 525-527
97. Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005; 12: 363-368 (Pubitemid 41192168)
98. Chevalier P, Rodriguez C, Bontemps L, et al. Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates. Cardiovasc Rest 2001; 50: 3486-3498
99. Kannankeril PJ, Roden DM, Norris KJ, Whalen SP, George AL Jr., Murray KT. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm 2005; 2: 134-140
100. Vyas H, Ackerman MJ. Epinephrine QT stress testing in congenital long QT syndrome. J Electrocardiol 2006; 39: S107-13. Review.
101. Roden DM, Iansmith DH. Effects of low potassium or magnesium concentrations on isolated cardiac tissue. Am J Med 1987; 82: 18-23 (Pubitemid 18119216)
102. Velavan P, Khan NK, Rigby AS, et al. Relation between severity of left ventricular systolic dysfunction and repolarisation abnormalities on the surface ECG: a report from the Euro heart failure survey. Heart 2006; 92: 255-256 (Pubitemid 43131974)
103. Thomas D, Hammerling EM, Wu K, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of asction. Br J Pharmacol 2004; 142: 485-494 (Pubitemid 38869862)
104. Dennis A, Wang L, Wan X, Ficker E. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 2007; 35: 1060-1063 (Pubitemid 350206429)
105. Guo J, Massaeli H, Li W, et al. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J Pharmacol Exp Ther 2007; 321: 911-920 (Pubitemid 46762679)
106. Hondeghem LM. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol 2006; 17: 337-340
107. Toga T, Kohmura Y, Kawatsu R. The 5-HT[4] agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene [hERG]-blocking activities. J Pharmacol Sci 2007; 105: 207-210